

FOR IMMEDIATE RELEASE

Affimed Announces Third Quarter 2014 Financial Results Conference Call

Heidelberg, Germany, November 11, 2014 – Affimed Therapeutics (Nasdaq: AFMD) today announced that on November 18, 2014, the Company will release its financial results for the quarter ended September 30, 2014. The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Tuesday, November 18, 2014 at 8:30 a.m. EST. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 2617286.

Local - Amsterdam, the Netherlands:	+31 (0) 20 716 8251
Local - Copenhagen, Denmark:	+45 32 71 16 64
Local – Frankfurt, Germany:	+49 (0) 69 2222 10635
Local - London, U.K.:	+44 (0) 20 3427 1928
Local - New York City, U.S.A.:	+1 646 254 3371
Local - Paris, France:	+33 (0) 1 76 77 22 35
Local - Zurich, Switzerland:	+41 (0) 44 580 7218

An audio webcast of the conference call can be accessed in the “Events” section on the “Media” page of the Affimed website at <http://www.affimed.com/events.php>. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.

About Affimed

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.

Contact:

Affimed Therapeutics
Adi Hoess, CEO
Phone: +49 6221 65307-0
E-Mail: IR@affimed.com